Colorado-based biotechnology firm BioAMPS International LLC announced Tuesday that it has received a $100,000 proof-of-concept investment from the University of Colorado's Technology Transfer Office. The funding, BioAMPS noted, is the result of an exclusive research license it signed with the university. According to BioAMPS, it will collaborate with CU Denver and the University of British Columbia to develop improved treatments for common, potentially lethal, drug-resistant bacterial infections. The research, BioAMPS added, centers around a family of antimicrobial peptides created by a pair of CU Denver researchers.
Top NewsWednesday, February 18, 2009
BioAMPS Lures $100K Investment for Research